Corvus Competitors
| CRVS Stock | USD 20.46 1.40 7.35% |
Corvus Pharmaceuticals vs SeaStar Medical Correlation
Very good diversification
The correlation between Corvus Pharmaceuticals and ICU is -0.36 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Corvus Pharmaceuticals and ICU in the same portfolio, assuming nothing else is changed.
Moving together with Corvus Stock
Moving against Corvus Stock
| 0.74 | ABP | Abpro Holdings | PairCorr |
| 0.67 | KURA | Kura Oncology | PairCorr |
| 0.66 | LYRA | Lyra Therapeutics | PairCorr |
| 0.59 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.53 | GNLX | Genelux Common | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Corvus Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Corvus Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Corvus Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Corvus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Corvus Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Corvus Stock performing well and Corvus Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Corvus Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 5.33 | (2.41) | 0.00 | (0.83) | 0.00 | 9.38 | 42.89 | |||
| BLRX | 2.59 | (0.27) | 0.00 | (0.19) | 0.00 | 5.20 | 13.04 | |||
| THAR | 5.48 | 0.50 | 0.08 | 0.40 | 5.92 | 11.55 | 40.06 | |||
| AIMD | 4.50 | (0.89) | 0.00 | (0.22) | 0.00 | 12.30 | 38.73 | |||
| OSRH | 6.34 | (0.17) | 0.00 | 0.02 | 6.57 | 15.25 | 43.23 | |||
| LPCN | 5.03 | 2.00 | 0.39 | (14.40) | 3.32 | 15.95 | 33.09 | |||
| ICU | 5.02 | (1.17) | 0.00 | (0.46) | 0.00 | 9.58 | 34.66 |
Cross Equities Net Income Analysis
Compare Corvus Pharmaceuticals and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| OSRH | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (3.3 K) | (35.4 K) | 403.8 K | (2.4 M) | (2.2 M) | (2.1 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.4 M) | 8.4 K | 7.5 K | 7.9 K |
| ICU | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (23 M) | (26.2 M) | (24.8 M) | (22.3 M) | (23.5 M) |
Corvus Pharmaceuticals and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Corvus Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Corvus Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Corvus Pharmaceuticals Competitive Analysis
The better you understand Corvus Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Corvus Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Corvus Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Corvus Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Corvus Pharmaceuticals Competition
Corvus Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Corvus Pharmaceuticals in relation to its competition. Corvus Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Corvus Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Corvus Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Corvus Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Corvus Pharmaceuticals position
In addition to having Corvus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.